| Project/Area Number |
17390402
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Kagawa University |
|---|
Principal Investigator |
TAMIYA Takashi Kagawa University, Faculty of Medicine, Professor (50252953)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NAGAO Seigo KAGAWA University, Faculty of Medicine, Professor (60100947)
KAWAI Nobuyuki KAGAWA University, faculty of Medicine, Assistant (40294756)
MIYAKE Keisuke KAGAWA University, faculty of Medicine, Assistant (00398033)
香川 昌弘 香川大学, 医学部, 助教 (30343312)
松本 義人 香川大学, 医学部附属病院, 助手 (80311827)
|
|---|
| Project Period (FY) |
2005 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥14,340,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2007: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2006: ¥3,800,000 (Direct Cost: ¥3,800,000)
Fiscal Year 2005: ¥5,600,000 (Direct Cost: ¥5,600,000)
|
|---|
| Keywords | embryonic cell / neural stem cell / glioma / gene therapy / transplantation / YKL-40 / embryonic stem cell |
|---|
| Research Abstract |
Previously, we evaluated the therapeutic efficacy of the prodrugs and chemosensitivity gene therapies for malignant gliomas. Recently we have evaluated human neural stem/progenitor cells (hNS/PCs) derived from embryonic stem cell as cell sources and some new genes for molecular therapies for malignant gliomas and other neurogenic disorders.
Firstly, we investigated the ability of neural stem/progenitor cells on dementia in the mouse model of nucleus basalis of Meynert lesion. This new therapy may be feasible for the treatment of Alzheimer's disease (J Med Invest 53 : 61-69, 2006).
Secondly, we examined the YKL-40 gene in human glioblastomas. Based on data from the microarray expression, the YKL-40 gene has been identified as one of the most over-expressed genes in human glioblastomas and the YKL-40 inhibited U87 cell growth, and a significant increase of U87 cells in the GI phase was observed. The gene therapy using the YKL-40 may be feasible for the treatment of malignant gliomas.
Recently, we have successfully evaluated human neural stem/progenitor cells (hNS/PCs) as cell sources for cell replacement therapies for neurological disorders, by examining the alteration of in vitro and in vivo property of long-term expanded hNS/PCs, and by evaluating tumorigenic potentials of hNS/PCs in vivo for up to 6 months by bioluminescent imaging and histological analysis.
|
